Skip to Content

Farxiga Approval History

Farxiga (dapagliflozin) is a selective sodium-glucose cotransporter-2 inhibitor for the treatment of adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Farxiga

Jan  8, 2014Approval FDA Approves Farxiga to Treat Type 2 Diabetes
Dec 12, 2013FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for Treatment of Type 2 Diabetes in Adults
Jul 25, 2013AstraZeneca and Bristol-Myers Squibb resubmit Dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S
Jan 19, 2012Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin
Oct 27, 2011U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months
Jul 20, 2011FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
Mar  8, 2011FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.